TG Therapeutics
TGTX
181 hedge funds and large institutions have $2.33B invested in TG Therapeutics in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 74 increasing their positions, 50 reducing their positions, and 24 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 50
43% more capital invested
Capital invested by funds: $1.63B → $2.33B (+$696M)
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
31% more call options, than puts
Call options by funds: $47.7M | Put options by funds: $36.5M
3% more funds holding
Funds holding: 175 → 181 (+6)
1.28% more ownership
Funds ownership: 67.96% → 69.24% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$98.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$84.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$76.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.6M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$28.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$91.2M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$39.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.9M |
| 4 |
EP
Eversept Partners
New York
|
-$34M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$29.2M |
TGTX Hedge Fund Activity: Q3 2020 in Review
181 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2020, worth a combined $2.33B — up 43% from $1.63B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new TGTX positions and 24 closed out — a net gain of 9 holders — while 74 added to existing stakes and 50 trimmed.
The largest buyer was Maverick Capital, adding an estimated $98.1M. The largest seller was RA Capital Management, cutting an estimated $91.2M.
- 181 institutional investors held TG Therapeutics (TGTX) as of Q3 2020, up from 175 in Q2 2020.
- Funds reported $2.33B of TG Therapeutics stock for Q3 2020, up 43% quarter-over-quarter.
- 33 funds opened new TG Therapeutics positions in Q3 2020 and 24 closed out, a net change of +9 holders.
- The largest TG Therapeutics buyer in Q3 2020 was Maverick Capital, an estimated $98.1M added.
- The largest TG Therapeutics seller in Q3 2020 was RA Capital Management, an estimated $91.2M sold.
Based on aggregated 13F filings for Q3 2020.